Novo Nordisk’s Oral Insulin Successfully Completes Early Study

Novo Nordisk A/S’s oral insulin successfully completed an early-stage study, according to the Danish drugmaker’s partner, Merrion Pharmaceuticals Plc, bringing what would be the first product of its kind a step closer to market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.